ASCO/EHA/ICML 2021 – Wojciech Jurczak
You are currently viewing a placeholder content from 3Q Video. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationWojciech Jurczak gives an overview of the advantages of new BTK inhibitors, the results of the ALPINE trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory CLL/SLL and talks about which new developments can be expected in the field of innovative BTK inhibitors in the treatment of CLL and other indications.
Here is the full ASCO/EHA/ICML 2021 report.
More posts
Preface – ASCO/EHA/ICML 2021
As virtual scientific conferences are becoming part of our daily routine as clinicians and researchers, information in individual areas of interest is easily accessible across different congresses.